Search PubMed⌕ Search

Biomedical subjects

H Eghbali

Publications and source records attributed to H Eghbali.

65 records · Page 4Linked to original sources
PubMed1982

Maintenance immunotherapy with BCG in non-Hodgkin's malignant lymphomas: a progress report of randomized trial.

Ninety-eight patients with non-Hodgkin's malignant lymphoma were first put into complete remission by a combination of chemotherapy and radiotherapy, and then received one course of chemotherapy as reinforcement. They were then randomized to receive either maintenance BCG therapy or no other treatment. Ninety-three patients were available for this analysis. There was a significant difference (P = 0.021) in relapse-free survival times between the two groups of patients. This difference is particularly significant in male patients, in patients ages 50-65 years, in all histologic classes, in patients treated after an initial relapse, and in clinical stages I and II. There was also a difference in crude survival, but the difference was not significant.

Aged↗
PubMed1982

Non-Hodgkin's malignant lymphomas: treatment of localized relapses with chemo + radio + BCG-therapy.

16 patients with relapsing non-Hodgkin's malignant lymphomas considered as clinical stage I or II were treated by an association of chemo + radiotherapy and thereafter by maintenance BCG therapy. 5 of them were included in a randomized trial and have a significantly different disease-free survival from patients receiving the same treatment but without BCG. 11 were systematically treated by BCG and they also have a fairly good disease-free survival. Such a treatment appears to be of value in treating these patients and even probably of curing some of them.

Adult↗
PubMed1980

Hodgkin's disease, clinical stages I and II. Results of radical irradiation with or without chemotherapy.

From 1965 to 1976, 170 patients with Hodgkin's disease, clinical stages I or II, were treated with radical irradiation. A first group of 42 patients was treated with irradiation alone, a second group of 24 patients received one course of chemotherapy followed by irradiation, and a third group of 104 patients was treated with a sandwich regimen including chemotherapy + irradiation + chemotherapy. Although the treatment were not randomized, the comparison of the results shows a striking improvement in the group submitted to the C + R + C regimen: in this group the plateau of disease-free survival was 90 per cent. This result was obtained after treatment for about 3 months without surgical staging or maintenance chemotherapy. However, this treatment may favor some complications,. mainly the development of a second malignancy; these risks may be decreased by reducing the treatment in patients with good prognosis.

Adult↗
PubMed1980

[Non-Hodgkin's malignant lymphomas. Clinico-pathological data and course in 370 patients (author's transl)].

Three hundred and seventy non-Hodgkin's malignant lymphomas were seen at the Fondation Bergoniéé between 1965 and 1978 and classified according to the Kiel classification. Pretherapeutic data and evolution allow to recognize three distinct pathologic groups: 1) a first type of lymphosarcoma, so-called "low grade malignancy", is observed only in adults and old patients; the disease is often disseminated, the evolution is slow and the prognosis favorable; 2) a second type, so-called "lymphoblastosarcoma", is only one observed in young patients, the evolution is fast with frequent leukemic transformation and this group is thus very close to acute lymphoid leukemia; 3) a third type, so-called "immunoblastosarcoma", is observed only in old patients; the evolution is fast but without major spread; for these two latter groups, the prognosis is unfavorable. This highly significant and clearcut distinction may be a help for scheduling treatment according to each group of patients.

Humans↗
PubMed1978

Malignant lymphoplasmacytoid lymphomas. Clinical and evolutive data.

A series of 31 cases of malignant lymphoplasmacytoid lymphomas (excluding Waldenström disease) is analyzed. Two-thirds of the patients initially had localizations elsewhere than in the lymph nodes and presented clinical stage I or II. The median survival is around 4 years and is particularly favorable for stage I and II patients who have received an association of radiotherapy and systematic chemotherapy; the estimated "cure rate" for these patients is around 80%.

Adult↗
PubMed1978

Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects.

The hematologic effects of combined chemotherapy and irradiation were analyzed in 70 patients with Hodgkin's disease stage I and II. The schedule used was as follows: one cycle of 15--21 days of chemotherapy immediately followed by irradiation, including mantle and lumboaortic fields. After a rest of one month, another cycle of the same chemotherapy was applied. The erythrocytes varied slightly; the leukocytes decreased during chemotherapy and were stable or increased slightly during irradiation. Platelets decreased slightly during chemotherapy and more markedly during irradiation. No major side effects were observed, and the regimen appeared well tolerated.

Adolescent↗
PubMedDate not supplied

Distinctive clinical features between lymphoblastic and immunoblastic non-Hodgkin's malignant lymphomas (Kiel's classification) in a series of 141 patients.

Out of a series of 427 NHML based on the Kiel classification and without previous treatment, 186 were of high grade malignancy and among them were 83 lymphoblastic (LB) and 58 immunoblastic (IB) lymphomas which were included in this study. The LB and IB, which represent the majority of high grade NHML, were compared regarding their clinical features and courses. Eight main criteria were significantly different between these two groups: age of patient, immunological history, mediastinal and pleural involvement, primary or secondary involvement of the bone marrow, secondary leukaemia, secondary meningeal involvement, and involvement of the facial region. Some of these differences (mediastinum and meningeal involvement) are related to subtypes within LB. The differences between these two groups suggest that different treatment programs may be warranted.

Adult↗
PubMedDate not supplied

[Bone localizations disclosing Hodgkin's disease. Apropos of 11 cases].

The authors report 11 cases of Hodgkin's disease in which the first sign was due to bone involvement. Such observations are rare and raise diagnosis delays (Means: 5, 6 months in this series). Modern medical imaging techniques (scintigraphy, CT scan, magnetic resonance imaging) are very useful to an earlier diagnosis which will be better confirmed by lymph node biopsy given the poor information yielded by osseous cytology and/or histology. The elective localisation in bones belonging to the axial skeleton seems to support the hypothesis of a contiguous osseous involvement from lymphoïd organs in contact with bones. Evolution with chemotherapy and radiotherapy is very similar to that observed in patients without bone involvement.

Adolescent↗
PubMedDate not supplied

[Course of follicular lymphomas in a series of 281 patients].

From 1963 to 1988, 281 patients suffering follicular lymphomas and without previous treatment were treated in the same institution. One hundred and thirty three had a localized disease (72 stages I, 61 stages II) ans 148 an extended disease (83 stages III and 85 stages IV). In the absence of dramatic therapeutic improvement quite all patients were treated in a homogeneous manner with radical radiotherapy for localized disease and palliative chemotherapy for extended ones. Median follow-up is 9 years. Ten year overall survival is 38% and relapse free survival 29.5%. Multivariate analysis show two main prognosis factors: age (+ or - 60 years) and tumoral mass (as shown by stage or number of involved area). Survival depends also on complete remission. Age and tumoral mass allows us to define three prognosis groups: favorable, intermediate, unfavorable. These groups justify different therapeutic approach and different proposals for prospective therapeutic trials.

Age Factors↗